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The implications of lipid lowering drugs in the treatment of diabetic nephropathy have been considered. At the
same time, the clinical efficacy of lipid lowering drugs has resulted in improvement in the cardiovascular functions
of chronic kidney disease (CKD) patients with or without diabetes, but no remarkable improvement has been
observed in the kidney outcome. Earlier lipid mediators have been shown to cause accumulative effects in diabetic
nephropathy (DN). Here, we attempt to analyze the involvement of lipid mediators in DN. The hyperglycemia-induced
overproduction of diacyglycerol (DAG) is one of the causes for the activation of protein kinase C (PKCs), which is
responsible for the activation of pathways, including the production of VEGF, TGFβ1, PAI-1, NADPH oxidases, and NFҟB
signaling, accelerating the development of DN. Additionally, current studies on the role of ceramide are one of the
major fields of study in DN. Researchers have reported excessive ceramide formation in the pathobiological conditions
of DN. There is less report on the effect of lipid lowering drugs on the reduction of PKC activation and ceramide
synthesis. Regulating PKC activation and ceramide biosynthesis could be a protective measure in the therapeutic
potential of DN. Lipid lowering drugs also upregulate anti-fibrotic microRNAs, which could hint at the effects of
lipid lowering drugs in DN.
Keywords: Diabetic nephropathy (DN), Protein kinase Cs (PKCs), Diacylglycerol (DAG), Glyceroshingolpids,
Antidyslipidaemic drugs and microRNAs (miRs)Review
Introduction
Abnormalities in the lipoprotein metabolism are associ-
ated with patients with diabetic nephropathy (DN) [1].
The lipoprotein abnormalities include a higher level of
very low-density lipoproteins (VLDL-c), low-density
lipoprotein-cholesterol (LDL-c) and a suppressed level
of HDL-cholesterol (HDL-c). Researchers have reported
that lipoprotein abnormalities are associated with the
development of glomeruloscerosis, a process that may
share similarities with atherosclerosis [2]. At the same
time, clinical studies have shown that in patients with
DN, lipid-lowering drugs could be associated with a
reduction in the proteinuria but not with a remarkable
improvement in the kidney outcome [3,4]. A high level
of LDL-cholesterol has been found to predict the develop-
ment of microalbuminuria in type 1 diabetes [5]. Clinical
studies on the association between hyperlipidemia and
renal dysfunction in patients with DN are difficult to* Correspondence: kkanasak@kanazawa-med.ac.jp
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unless otherwise stated.perform due to the complex interrelationship between
serum lipids, blood glucose, and proteinuria. Watts et al.
found that the development of microalbuminuria in a
10-year follow-up was closely related to the baseline
serum cholesterol and LDL cholesterol levels [6] in a
study on 53 normoalbuminuric type 1 diabetic patients.
Parving et al. also found a close association between the
serum cholesterol level and progression of renal dysfunc-
tion in a 10-year prospective study in type 1 diabetic
patients with nephropathy [7]. The baseline level of serum
cholesterol was also found to be the independent risk
factor for the development of DN in studies of patients with
type 2 diabetes [8]. In epidemiologic studies of individuals
with glomerular disease or DN, hyperlipidemia predicted
a faster loss of kidney function [9]. Krolewski et al. [10]
evaluated predictors of fast progression (creatinine after 3
years of follow-up/baseline creatinine 41.5) in 424 individ-
uals with type 1 diabetes and proteinuria. The proportion
of individuals with fast progression was 29% in those with
a baseline total cholesterol of 180 mg/dl, 24% for 180 to
219 mg/dl, 38% for 260 to 299 mg/dl, and 48% for >300
mg/dl [10,11]. The findings persisted after controlling for
blood pressure; however, the studies did not control forral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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baseline total cholesterol (HR (hazard ratio) 1.96 per
100 mg/dl ml higher) and LDL cholesterol (HR 1.47 per
50 mg/dl higher) were associated with a higher risk of
progression to end-stage renal disease [12]. It is unclear
from the report whether they controlled for baseline
proteinuria. The issue of whether the prior studies con-
trolled for proteinuria is relevant given the strong cor-
relation between the serum cholesterol levels and renal
albumin clearance [13].
The beneficial effects of statins on DN progression
also remain unclear due to the lack of prospective,
randomized intervention studies. Early studies have dem-
onstrated that treatment with the HMG CoA reductase
inhibitor pravastatin decreases albuminuria in patients
with type 2 diabetes [14,15]. However, later studies showed
the beneficial effects on albuminuria with HMG CoA
reductase inhibitors (simvastatin) in both type 1 or type
2 patients [16,17]. These studies involved only a small
number of patients, and the follow-up duration was
short, making it inadequate for assessing the clinical
effects of lipid control in DN.
Lipid mediators as modulators of renal physiology
The families of prostaglandins, leukotrienes, and related
compounds are called eicosanoids and are derived from
20-carbon polyunsaturated fatty acids (dihomo-γ-linolenic
acid, arachidonic acid, or eicosapentaenoic acid [EPA]).
These compounds have extremely widespread and diverse
biological effects, some of which may be of great import-
ance in the pathophysiology of renal disease. The prosta-
glandins PGE2 and PGI2 help maintain renal blood flow
and glomerular filtration in clinical conditions that are
associated with renal functions, and they are generally
considered beneficial. PGI3 has been reported to have a
similar efficacy to PGI2. Conversely, thromboxane A2
(TXA2) decreases renal blood flow and glomerular filtra-
tion [18]. Remarkable increases in the renal production
of prostaglandins and/or TXB2 have been reported in
humans with chronic renal disease and various animal
models of renal disease [19]. Pharmacological or dietary
intervention to alter these changes in eicosanoids may
provide a means of modifying the disease process. The
inclusion of fat sources rich in EPA (for example, marine
fish oils) would be expected to decrease the production of
dienoic prostaglandins and increase that of the trienoic
series [20]. Dietary fish oil supplementation is beneficial in
some animal models of renal disease that involve an
immune component, for example, murine lupus [21]. A
remarkable decrease in the production of dienoic eicosa-
noids and the increased production of PGE3 (although
levels were much lower than those of the dienoic com-
pounds) were noted with fish oil supplementation in one
of these studies [21]. It is of interest that a diet high inlinoleic acid was beneficial in another subtotal nephrec-
tomy study in rats, although such kind of beneficial effect
of linoleic acid was observed in the absence of changes in
the urinary excretion of dienoic eicosanoids [22]. Further
studies are needed to better evaluate the potential for
using polyunsaturated fatty acids in naturally occurring
diseases in other species.
Role of PKC activation in DN
Protein kinase C (PKC) is involved in signal transduction
pathways, cell proliferation, differentiation, cell cycle, and
apoptosis. However, the role of PKC in kidney disease has
not yet been fully defined. The PKC activation induced by
hyperglycemia is likely due to the increase in the 1,2-diac-
ylglycerol (DAG) levels, a physiological activator of PKC,
although other co-factors such as phosphatidylserine (PS)
or phorbolester (PE) are also known stimulants. Inactiva-
tion of the PKC isoforms has been found to counteract
many hyperglycemia associated vascular dysfunctions in
the kidney [23]. The PKC family has 13 isoforms, which
have been classified into three subfamilies based on their
mode of activation. The group of classical or conventional
PKC (cPKC) consists of the α, βI, βII, and γ isoforms, all
of which depend on calcium (Ca++), DAG or its analogue
phorbol 12-myristate 13-acetate and, in most cases, phos-
phatidyl serine (PS) for activation. The isoforms that are
independent of Ca++ but require DAG and PS are classi-
fied as the new PKC (nPKC), and include the subtypes δ,
ε, η, and θ. The third group of isoforms is that of the atyp-
ical PKC (aPKC) ξ, ι/λ, ν, and μ. Their activation does not
require Ca ++ or DAG; they only require PS. Figure 1 de-
picts the different sources of DAG production and effects
on PKC activation. The activation of PKC (β and δ form)
leads to the initiation of many pathological processes
responsible for the development of DN. The pathological
processes include production of VEGF, TGFβ1, PAI-1, and
NADPH oxidases and activation of the NFҟB signaling
pathway. Once activated, PKC can transmit signals to the
nucleus via different signal transduction pathways. For
example, the mitogen-activated protein kinase (MAPK)
cascade may be activated. Such diverse functions as cell
proliferation, differentiation and cell death are outcomes
of particular MAPK members: Raf-1 can be activated by
Ras in some cases after crosstalk with PKC; activated
extracellular signal regulated kinases can in turn activate
transcription factors such as myc, myb, fos, and jun,
thereby enabling the expression of genes encoding en-
zymes required for key metabolic functions, such as
cell proliferation and invasion; and the JNK pathway
often initiates cell death, which, in some cases, is stim-
ulated by PKC isoforms, as recently reviewed by Li and
Gobe [24].
Koya et al. reviewed the activation of PKC-associated
development of diabetic complication [25]. The inhibition
Figure 1 Multiple sources of diacylglycerol (DAG), and DAG-mediated PKC activation could contribute to renal fibrosis. Overproduction
of DAG causes the activation of PKC, leading to the initiation and development of diabetic nephropathy (DN). PKC (β and δ form) primarily
upregulates the NFҟB gene, TGFβ1 action, VEGF, PAI, and NADHP oxidases pathway. Increased TGFβ1, collagen, fibronectin enhanced mesangial
expansion, activated NFҟB induce profibrotic gene expression, and activated VEGF cause enhanced angiogenesis, and upregulated PAI reduces
fibrinolysis, whereas increased NADPH oxidase provides oxidative stress to renal cells; all of these factors could contribute to the development of
renal fibrosis.
Srivastava et al. Fibrogenesis & Tissue Repair 2014, 7:12 Page 3 of 10
http://www.fibrogenesis.com/content/7/1/12of PKCβ, a common molecule in diabetes-related renal
and vascular injury, holds promise as a novel strategy for
improving micro- and macro-vascular complication out-
comes in diabetes [26]. Key mechanisms in the pathogen-
esis of vascular dysfunction in DN are ROS formation
followed by the activation of specific isoforms of PKC.
The de novo formation of DAG during hyperglycemia
activates PKC. Acute hyperglycemia caused the activation
of PKC, which could also be associated with rapid endothe-
lial impairment in DN. In the STZ rat model, blockade of
the PKCβII isoform with LY333531 prior to hyperglycemia
protected nitric oxide formation within the arteriolar wall
[27]. Additionally, the increased secretion of inflammatory
molecules as a result of hyperglycemia induced PKCs acti-
vation, which is involved in oxidative stress and associated
with vascular dysfunction in DN. The findings from various
studies support an association between the increased
secretion of inflammatory molecules, such as cytokines,
growth factors, and metalloproteinases, and the develop-
ment of DN [28,29].
Ceramide in DN
Ceramides are highly abundant in the kidney, and they
regulate various cellular processes, including cell prolif-
eration, apoptosis, inflammation, and cellular signaling.Ceramide consists of N-acetylated (14 to 26 carbons)
sphingosine (16 to 18 carbons). Figure 2 depicts the role
of sphingomyelin in the development of kidney disease.
The role of sphingomyelin and ceramide in renal physi-
ology was previously reviewed by Hao and Breyer [30,31].
Ceramide is mainly produced from the hydrolysis of
sphingomyelin, which is catalyzed by sphingomyelinase
[32]. Ceramide can also been generated through the
condensation of sphingosine or sphinganine and fatty
acyl-CoA by ceramide synthase [32]. The direct targets
of ceramide are ceramide-activated protein phosphatase,
ceramide-activated protein kinase, and protein kinase Cξ.
Previous studies have shown that ceramide is involved
in the pathogenesis of acute kidney injury caused by
ischemic reperfusion, toxic insults, and oxidative stress
[33]. In a normal mouse kidney cortex, C24, C22, and C16
ceramides have been identified [34]. Ischemia/reperfusion
or nephrotoxic injury (glycerol-mediated myohemoglobi-
nuria, radiocontrast) causes a transient reduction in the
renal ceramide levels, which is followed by a two- to
three-fold increase in the ceramide levels [35]. The in-
creased ceramide after renal injury is not associated
with the enhanced hydrolysis of sphingomyelin because
sphingomyelinase expression was not increased (instead, it
is decreased) in the experiments [33]. In contrast, hypoxia
Figure 2 Schematic presentation of ceramide synthesis and its involvement in renal fibrosis. Ceramide is synthesized mainly by three
processes: de novo synthesis, the salvage pathway, and sphingomyelin hydrolysis. Ceramide could cause renal fibrosis by enhancing ECM production,
glomelular injury, proteinuria, and apoptosis. Triglycerides (TGs) and cholesterol (CHOL) accumulation in the kidney could also contribute to the
development of renal fibrosis. At the same time, sphingosine kinase could contribute to renal fibrosis by enhancing cell migration and proliferation.
The renoprotective activity of amitriptyline is due to its ability to inhibit the sphingomyelinase enzyme and thereby inhibit ceramide synthesis and to
protect against renal fibrosis.
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thelial cell injury is attenuated by the ceramide synthase
inhibitor, fumonisin B1, suggesting that increased cer-
amide synthase activity is responsible for the increased
ceramide generation, leading to apoptotic change of the
renal epithelial cells [35,36]. Achar et al. found that the
tricyclic antidepressant amitriptyline inhibited inflamma-
tion, myofibroblast formation, and several other indices of
renal fibrosis in ureterally obstructed (UUO) mice [37].
Additionally, there were significant reductions in the
expression of α-smooth muscle actin (α-SMA), osteopontin,
transforming growth factor-β (TGFβ), monocyte chemotac-
tic protein-1 (MCP-1), and intercellular adhesion molecule-
1 due to amitriptyline treatment in UUO mice [38]. These
pleiotropic antidepressant agents have antifibrotic effects
in the kidney and other organ systems. Antidepressants
accomplish reduction in kidney fibrosis by several mech-
anistic possibilities, such as by reducing inflammation, the
number of natural killer cells, inflammatory cytokines,
chemokines, H-1 receptor, and acid sphingomyelinase
activity [39] or increasing anti-oxidant activity in the
UUO mice [37]. Amitriptyline can degrade acid sphingo-
myelinase, an enzyme contributing to ceramide formation,
and degradation of acid sphingomyelinase could be help-
ful in the treatment of DN. Achar et al. [40] studied the
renoprotective effect of amitriptyline in UUO mice. Thebeneficial effect of amitriptyline in the UUO study by
Achar et al. [40] could be an inhibition of acid sphingo-
myelinase that, in turn, inhibits tubular-cell apoptosis and
is interstitial in inflammation. A gene knock out experi-
ment to study acid sphingomyelinase would helpful for
understanding the protective effect of amitriptyline. Based
on the aforementioned reports, we conclude that such a
pleiotropic effect of the tricyclic anti-depressant would be
a therapeutic challenge in DN.
Antidyslipidemic drugs in DN
As in the previous Japanese atherosclerosis society (JAS)
guidelines of 2007, an LDL goal of <120 mg/dl has been
set for the high-risk primary prevention patients, and a
goal of <100 mg/dl is recommended for secondary pre-
vention patients. Therefore, physicians need to help
secondary prevention patients in particular achieve the
current LDL-c targets using standard lipid management
strategies, which can be followed by a more stringent
treatment approach. The effect of statins in renal disease
have been discussed in detail in many reviews [41,42].
Table 1 summarizes the beneficial effects of lipid lowering
drugs on renal outcomes. It is interesting that some of the
beneficial effects of statins can be independent of the chol-
esterol reduction [43]. Different classes of statins can pro-
vide renoprotective activity. The potential renal protective
Table 1 Effect of lipid lowering drugs on the renal outcome
Drugs Effect on renal outcome References
Statins and Fenofibrate Reduction in urinary albumin [3,4]
Atorvastatins with combine therapy with
glycaemic control
Inhibit cardiovascular and renal end points by 50% in DN patients [46]
Pitavastatin and Pravastatin Reduction in urinary albumin in DN patients [44]
Pitavastatin is more effective than Pravastatin
Rosuvastatin Reduction in albuminuria, oxidative stress, and serum cystatin C levels
in DN patients
[45]
Atorvastatin Not remarkable difference in renal functions between those taking
high or low dose atorvastatin over 2 years
[46]
Atorvastatin Atorvastatin was effective at decreasing CVD in those with and
without a moderately decreased eGFR
[47]
Fenofibrate Not remarkable difference in GFR, Provide reno-protection in
moderate renal impairment patients
[56,58]
Fenofibrate Inhibit risk of albuminuria in patient with diabetes [59]
Fenofibrate Acute change in creatinine not associated with adverse effect on
renal outcome
[56,57]
Simvastatin (and simvastatin + ezetimibe) Does not produce remarkable reductions in measures of renal
disease progression
[61-63]
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amelioration of endothelial function through nitric oxide
(NO) production and changes in blood rheology. The
difference in the renal protective effects of different
class of statins are not clearly known in DN lipid-related
mechanisms, but this could be due to the statins different
pharmacological, pharmacokinetic properties, bioavailabil-
ity, and distribution in the tissues. A randomized compari-
son of pitavastatin and pravastatin treatment on the
reduction of urinary albumin in patients with type 2 dia-
betic nephropathy was studied [44]. Pitavastatin was more
effective than pravastatin in reducing albuminuria in type
2 diabetic patients with early-stage diabetic nephropathy
[44]. Rosuvastatin administration reduced albuminuria,
oxidative stress, and the serum cystatin C levels, inde-
pendent of blood pressure or lipid levels in DN patients
[45]. Protection Against Nephropathy in Diabetes with
Atorvastatin (PANDA), a randomized, double-blind pla-
cebo-controlled trial of high- versus low-dose atorvastatin
(1) studies, reported no significant difference in the renal
functions between those taking high or low doses of ator-
vastatin over 2 years [46]. Another report on the effects of
atorvastatin on kidney outcomes and cardiovascular dis-
ease in patients with diabetes, an analysis from the Collab-
orative Atorvastatin Diabetes Study (CARDS), revealed a
beneficial effect of atorvastatin on the estimated glomeru-
lar filtration rate (eGFR), particularly in patients with albu-
minuria [47]. Atorvastatin was effective at decreasing
CVD in those with or without a moderately decreased
eGFR and achieved a high absolute benefit [47].
In an elegant study by Zoja et al. [48], the authors re-
ported that a combined angiotensin converting enzymeinhibitor and statin therapy had a remarkable anti-
proteinuric effect with a significant improvement in the
renal function in a severe rat model of passive Heymann
nephritis (PHN). The drug combination limited glomeru-
losclerosis, tubular damage, and interstitial inflammation
compared with placebo or drugs alone.
In vitro studies have clearly established that statins influ-
ence important intracellular pathways that are involved in
the inflammatory and fibrogenic responses [43]. Statins
also inhibit the proliferation of cultured mesangial cells
and renal epithelial tubular cells through their ability to
suppress the formation of intermediate metabolites of the
mevalonate pathway, particularly the nonsterol isopre-
noids, which seem to be essential in cell replication [49].
Multifactorial strategies that combined glycemic therapy,
lipid lowering, blood pressure (BP) control, and aspirin
reduced both the cardiovascular and renal end points by
50% in patients with diabetes and microalbuminuria [50].
Recently, lipid lowering agents in chronic kidney disease
were reviewed by researchers, which was of great interest
for us [51]. Statins remarkably improve cardiovascular dis-
ease (CVD) and the associated mortality in patients with
CKD both with and without diabetes who do not require
dialysis [52,3]. Statin treatment protects from the injuries
caused by the DAG-Activated PKC activation in a variety of
ways. These pleotropic effects of statins include improve-
ment in the endothelial function, reduction in the oxidative
stress, reduction in the TGFβ1 level, decline in the level of
inflammatory cytokines and sensitization of the Akt/PI3
kinase pathways, inducing the GLUT 4 translocation
reviewed by Danesh and Kanwar [53]. The effect of lipid
lowering drugs on ceramide formation is not well known.
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hypertriglyceridaemia with residual elevation of non-HDL
cholesterol. However, the role of fibrates in patients with
CKD has yet to be determined [54]. Investigators in the
Fenofibrate Intervention and Event Lowering in Diabetes
(FIELD) study [55] randomly allocated [56] 795 partici-
pants with type 2 diabetes mellitus to either fenofibrate
(200 mg daily) or placebo, with a median follow-up period
of 5 years. In this study, fenofibrate treatment reduced the
total cardiovascular events (HR 0.89, 95% CI 0.80-0.99)
[55]. This benefit did not differ significantly between
groups that had different eGFRs. In another report, the
researchers summarized that fenofibrate should be con-
sidered as an additional therapeutic option, along with
conventional risk-factor management, to further reduce
CVD events and mortality and provide reno-protection
to patients with diabetes and to those with moderate
renal impairment [4]. In a meta-analysis, fibrates reduced
the risk of albuminuria progression in patients with dia-
betes and reduced the risk of major cardiovascular events
and cardiovascular death (but not all-cause mortality) in
patients with an estimated glomerular filtration rate of 30
to 59.9 mL/min/1.73 m2 [57]. Fibrates also increase the
serum creatinine level after therapy initiation, but this
effect could be a response to the blunting of creatinine
secretion rather than to true renal injury [58]. In a post-
trial analysis of the FIELD and ACCORD datasets, acute
changes in the creatinine level with fibrate therapy were
not associated with adverse effects on the major clinical
renal outcomes.
Researchers introduced a Study of Heart and Renal
Protection (SHARP) study, was a double-blind, placebo-
controlled trial that aimed to assess the safety and efficacy
of reducing LDL cholesterol in more than 9,000 patients
with chronic kidney disease (approximately 3,000 of
whom were on dialysis at randomization) [59,60]. Among
the CKD patients, the most common recorded cause of
renal disease was glomerulonephritis (19%), diabetic
nephropathy (15%) and hypertensive or renovascular
disease (20%) [61]. Among the 6,000 patients who were
not receiving dialysis at randomization, the average
eGFR was 26.5 (SD 13.0 mL/min/1.73 m2, approximately
two-fifths of the patients who were not on dialysis had
kidney disease outcome quality initiative stage 3 disease.
Among the non-dialysis patients who had a measurement
of the urinary albumin to creatinine ratio (ACR), ap-
proximately one-fifth had a value in the reference
range (ACR <30 mg/g), two-fifths had microalbumi-
nuria (ACR >30 mg/g), and two-fifths had macroalbu-
miuria (>300 mg/g) [61]. In high-risk populations (such as
patients with diabetes), observational studies have shown
that there is an approximately log-linear relationship be-
tween the risk of death from cardiovascular disease and
blood cholesterol, but an analogous association has notbeen demonstrated in with CKD. In the study, associa-
tions between blood cholesterol and cardiovascular
mortality were found on a logarithmic scale, among
the screenees in the Multiple Risk Factor Intervention
Trial (MRFIT) with diabetes (N = 5000) and without
diabetes (N = 340,000) [59]. The study authors also
aimed to assess whether lowering LDL cholesterol reduced
the rate of loss of renal function in people with CKD, with
or without diabetes, who had not commenced dialysis
treatment [59,60]. Patients were randomly assigned to re-
ceive simvastatin 20 mg plus ezetimibe 10 mg daily versus
matching placebo. SHARP concluded that approximately a
quarter of all heart attacks, strokes, and operations to open
blocked arteries could be avoided in people with CKD by
using a combination of ezetimibe and simvastatin to lower
the blood cholesterol levels [59]. Of the approximately
6,000 patients who were not on dialysis at randomization,
allocation to simvastatin plus ezetimibe did not produce
significant reduction in any of the prespecified measures of
renal disease progression. End stage renal disease is defined
as the commencement of maintenance dialysis or trans-
plantation; end stage renal disease or death; and end stage
renal disease or doubling of baseline creatinine [61].
MicroRNAs as new regulatory molecules targeted by lipid
lowering drugs
MicroRNAs play an important role in the pathogenesis
and regulation of kidney diseases [62,63]. MicroRNAs
are non-coding, single strands of 22 nucleotides that
exert posttranscriptional control on gene expression by
pairing their seed sequences (2 to 8 nucleotides at the 5′
end) to complementary sequences that are typically in
the 3′ untranslated region of target mRNAs. This pairing
results in the degradation of the target mRNA and/or the
inhibition of its translation. Figure 3 depicts a summary of
the microRNA regulation over antidyslipidaemic drugs and
renal fibrosis. Statin treatment activates the expression of
the miR-143/145 cluster through KLF2 (Kruppel-like family
of transcription factor, the zinc finger family of DNA-
binding transcription factor) in ECs [64]. MiR-143 and
miR-145 are intergenic miRNAs that control the vascular
smooth muscle cell (VSMC) phenotypic switch, tumori-
genesis, and adipocyte differentiation [65]. ApoE knockout
mice showed low levels of vascular miR-143/145 [66]. For
instance, the miR-143 to 145 gene locus, which encodes
both miR-143 and miR-145, is transcriptionally regulated
by a complex composed of serum response factor (SRF)
and myocardin or myocardin related transcription factors
(MRTFs) [67,68]. TGF-β and BMP signaling increase miR-
143 and miR-145 by activating the myocardin and MRTF,
respectively [68]. Recently, atorvastatin was found to be
associated with the upregulation of SIRT-1 expression via
the inhibition of miR-34a [69]. The study elucidated a
new mechanism by which statin therapy could improve
Figure 3 Implications of antidyslipidemic drugs on the antifibrotic-miRs in the protective measures of DN. Altered microRNA expression,
as a result of a deregulated lipid metabolism, inflammation, oxidative stress, high blood pressure, proteinuria, and high blood glucose could cause DN
by activating transforming growth factor β (TGFβ) signaling. An elevated DPP-4 level, BMP signaling, and claudin-1 could also be associated with DN.
Atorvastatin improves cardiovascular functions by elevating miR-let-7i. miR-let-7i is associated with inhibiting TGFβ signaling. Farnesoid X receptor
(FXR) is known to activate miR-29a, reducing DPP-4 and the associated renal fibrosis. Statins also elevate SIRT1 by inhibiting miR-34a. SIRT1 inhibits
claudin-1 and associated renal fibrosis.
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tor of SIRT1, which promotes endothelial senescence.
Renal tubular SIRT-1 attenuates diabetic albuminuria by
epigenetically suppressing Claudin-1 overexpression in
podocytes [70]. Atorvastatin improves CVD function by
ameliorating miR-let7i level. Our research group recently
suggested that the miR-let7s-FGFR1 axis inhibits TGFβ
signaling [71]. Similarly, lovastatin ameliorates miR-33
family members, which in turn inhibit SREBP-2 and chol-
esterol synthesis. Farnesoid X Receptor (FXR) deficiency
was found to cause diabetes to accelerate in type 1 DN
mice [72]. FXR inhibits SREBP-2 and elevates miR-29a,
thereby ameliorating renal fibrosis [73]. miR-29s have
been shown to ameliorate renal fibrosis by downregulating
the DPP-4 level [74]. The exact mechanisms by which
FXR works to protect DN are not known, but elevating
miR-29a could be one possibility [72].
Perspective
The connection between atherosclerosis and glomerulo-
sclerosis was suggested approximately 20 years ago by
Diamond, who envisaged the foam cell, that is, the lipid
overloaded macrophage, as the pivotal factor in both
atherosclerosis and glomerulosclerosis [75,76]. Clinical
studies suggest that lipid lowering drugs improve thecardiovascular functions in the DN patients, but no re-
markable improvement has been found in the kidney
outcome [4,5]. At the same time, clinical data revealed a
reduction in the proteinuria in the statin-treated DN
patients. Large-scale clinical trials that are prospective,
randomized, and controlled are still lacking. Lipid control
appears to be important in the prevention and treatment
of DN. Targeting DAG over-production mediated PKC ac-
tivation would allow for the utilization of cellular signaling
pathways, which would be helpful for further studies on
the control of DN. We previously discussed the role of cer-
amide and its effect on causing kidney disease. Targeting
ceramide metabolism would be a therapeutic challenge in
DN. Considering the microRNAs that target ceramide
biosynthesis, degradation, and signaling mechanism, we
could explore new insights and understandings into their
role in the therapeutics of DN.
Conclusion
The present review describes various aspects and impli-
cations of lipid lowering drugs in the treatment of DN.
Enhanced PKC activation, as a result of hyperglycemia-
mediated DAG production and an increased rate of
ceramide synthesis, is associated with impairment in
renal functions. Targeting PKC activation and ceramide
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At the same time, treatment with lipid lowering drugs
contributes to the upregulation of antifibrotic microRNAs
and associated mechanisms, which would affect the thera-
peutic potential in DN.
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of transcription factor; LDL-c: Low-density lipoprotein cholesterol;
MRTFs: Myocardin related transcription factors; MAPK: Mitogen activated
protein kinase; MCP-1: Monocyte chemotactic protein-1; NO: Nitric oxide;
nPKC: New PKC; PANDA: Protection Against Nephropathy in Diabetes with
Atorvastatin; PKCs: Protein kinase C; PAI-1: Plasminogen activator inhibitor-1;
PS: Phosphatidylserine; PE: Phorbolester; PPARα: Peroxisome proliferator-activated
receptor; PRK: PKC related kinases; PHN: Passive Heymann nephritis; ROS: Reactive
oxygen species; SIRT1: Sirtuin1; SHARP: Study of Heart and Renal Protection;
SRF: Serum response factor; SERBP: Sterol-Regulator Element-Binding Proteins;
TGFβ1: Transforming growth factor β1; TXA2: Thromboxane A2; VEGF: Vascular
endothelial growth factor; VSMCs: Vascular smooth muscle cells.
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